Gary Millerchip

One-line summary: CFO of Costco Wholesale; Q3 FY2026 earnings source for memory chip cost headwinds (DRAM pass-through at retail), GLP-1 pharmacy market share gains (Wegovy/Ozempic), and AI search triple-digit growth with highest site conversion rate.

Role / affiliation

Chief Financial Officer, Costco Wholesale Corporation (NASDAQ: COST).

Key claims

• gary-millerchip in 2026-05-28-earnings-cost-q3-fy2026: "higher cost of memory chips in computers having an impact on the sort of cost of items in majors" — downstream consumer-channel confirmation that DRAM spot price increases are flowing through to electronics retail pricing.
• gary-millerchip in 2026-05-28-earnings-cost-q3-fy2026: "Pharmacy led the way and saw significant market share gains in the quarter. In addition... factors... include increased GLP-1 demand, and inclusion of Wegovy and Ozempic in our Member Prescription Program" — institutional-scale GLP-1 demand pull at the consumer distribution layer.
• gary-millerchip in 2026-05-28-earnings-cost-q3-fy2026: "triple digit growth in Q3, and this activity had the highest conversion rate of all traffic coming to our site" [AI-powered search / digital engagement]

Related

• cost
• ron-vachris
• hbm-cowos-as-binding-bottleneck — DRAM cost pass-through corroboration
• glp1-injectable-supply-chain-bottleneck — GLP-1 pharmacy demand confirmation

Sources

• 2026-05-28-earnings-cost-q3-fy2026 — Q3 FY2026 earnings call